Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential IROX and Etoposide/Carboplatin in Extensive SCLC
NCT00240097Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2005
- Primary completion
- Jun 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in small cell lung cancer (SCLC), sponsored by University of Alabama at Birmingham. Started Jun 2005; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00240097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240097.